Personalized medicine company Proventys said Wednesday that it has closed on a $5.65 million round of venture financing, hired a new CEO and reached a deal with health-care giant McKesson. Durham-based Proventys makes software that uses information from patients’ medical records to determine how cancer patients will react to chemotherapy. The company was founded in 2005 by Ralph Snyderman, the former chief executive of Duke University Health System.
